Serum HMGB1 levels decreased significantly in a median of 3 months after presentation but then returned to levels similar to those found at baseline and no significant fluctuation was seen over time in AAV patients, not prior to or during disease relapses. Here, HMGB1 is linked to anti-neutrophil cytoplasmic antibody-associated vasculitis.